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Background: Implantable cardioverter defibrillators (ICDs) are indeed beneficial in selected patients
as evidenced by multiple large randomized controlled trials (RCTs) since 1980. A systematic method for
stratification of patients and hospital-wide criteria/guidelines to ascertain appropriate device implantation
became necessary.
Methods: Major ICD/CRT (cardiac resynchronization therapy) clinical studies and relevant guidelines
were reviewed, and an institution-wide inclusion and exclusion criteria for ICD/CRT was formulated.
A retrospective analysis of selected cases was performed to discuss the criteria and special clinical situations.
Results: We have translated the evolving ICD/CRT studies into a standard of care at our hospital by
formulating a standard, practical, and update-to-date ICD inclusion and exclusion criteria. Thirteen cases
were selected to represent major indications and contraindications of ICDs in our practice. These cases cover
indications of ICD for secondary prevention of sudden cardiac death (SCD), primary prevention of SCD in
patients with CHF resulted from either ischemic or non-ischemic cardiomyopathy, as well as for infiltrative
cardiomyopathy and inherited conditions. We discussed the application of CRT in patients with CHF
associated with prolonged QRS duration. We then covered the potential benefits of ICD with/without CRT in
certain special populations of patients that have not been adequately evaluated by currently available RCTs;
these include alcoholic, elderly, female, and ESRD/HD patients. Finally, we addressed risks, complications
and contraindications of ICD, as well as application of an external wearable defibrillator in AMI, or status
post-CABG patient during the mandatory waiting period for an ICD.
Conclusions: Establishment of the ICD/CRT criteria represents a practical translation of emerging CRTs and
helps to standardize patient care in our hospital. It also improves cost-effectiveness as well as appropriate
utilization of institute and device resources.
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S
ince the first clinical use of the implantable
cardioverterdefibrillator (ICD) in 1980, multiple
large randomized controlled trials (RCTs) have
been conducted, and ICD guidelines and indications for
various patient populations have been emerging as these
RCTs conclude. ICDs are indeed beneficial in selected
patients; hence, a thorough understanding of indications
is critical for daily practice.
Inthisarticle,wepresentaretrospectiveanalysisonhow
evolving ICD/cardiac resynchronization therapy (CRT)
studies have translated into a standard of care at our
community-based hospital by guiding us to formulate
standard,practical,andupdate-to-dateICDinclusionand
exclusion criteria. Before the establishment of these
criteria, there was no systematic method for stratification
of patients, and decisions were limited to the discretion of
thecardiologist,sometimeswithlittleornoinvolvementof
the cardiac electrophysiologist. This situation necessitated
a hospital-wide policy to ascertain appropriate device
implantation criteria and guidelines for all patients. After
the establishment and execution of the criteria that will be
discussed in detail in this paper, the adherence and com-
pliance with current recommendations from CRT trials
andstandardnationalguidelineshasbecomecloseto100%
in our hospital. Cost-effectiveness has greatly improved;
institute and device resources are now better utilized.
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Since 1980, multiple large RCTs have been conducted.
AVID (Antiarrhythmic Versus Implantable Defibrillator)
(1) concluded that the ICD is superior to medication for
secondary prevention of ventricular tachycardia (VT)/
ventricular fibrillation (VF). The survival benefit with
ICD implantation in comparison with standard medical
therapy for secondary prevention of VT/VF has been
replicated by two smaller trials [CIDS (2) and CASH (3)].
These findings have established the secondary prevention
of sudden cardiac death (SCD) as a Class I indication for
ICD placement.
As for primary prevention of SCD, the MADIT
(4), MADIT-II (5), and MUSTT (6) trials showed that
ICDs significantly improved survival in high-risk patients
with coronary artery disease (CAD) and ischemic car-
diomyopathy. High risk is defined as: CAD, prior myo-
cardialinfarction,leftventricularejectionfraction(LVEF)
no greater than 35%, non-sustained VT on ambulatory
monitoring, VT inducible by programmed stimulation,
and failure of intravenous procainamide to prevent
inducibility. In contrast, CABG Patch (7) showed ICDs
do not improve survival in high-risk patients after CABG
up to 32 months; DINAMIT (8) showed ICD therapy
does not reduce overall mortality in high-risk patients
who have recently had acute myocardial infarction (AMI)
up to 40 days.
The DEFINITE trial (9) showed a strong trend toward
ICD benefit over the standard-therapy group for non-
ischemic cardiomyopathy. SCD-HeFT (10) was the largest
primary prevention ICD clinical trial, which recruited
patients with either non-ischemic or ischemic cardiomyo-
pathy, LVEF B35%, and New York Heart Association
(NYHA) functional Class II or III congestive heart failure
(CHF). It concluded that ICD reduced overall mortality
by 23% in CHF patients. SCD-HeFTalso defined patient
selection for ICD therapy to patients with LVEF B35%
and NYHA Class II or III CHF.
Despite the lack of large-scale RCTs, ICDs are usually
a Class IIa recommendation for patients with uncom-
mon conditions such as infiltrative and inherited diseases
that are associated with a high risk of SCD. Infiltrative
diseases include cardiac sarcoidosis, and less commonly,
amyloidosis. An ICD is indicated when the conditions are
accompanied by sustained or non-sustained VT, regardless
of LVEF. Inherited cardiac diseases include hypertrophic
cardiomyopathy (HOCM), arrhythmogenic right ventri-
cular dysplasia, Brugada syndrome, long QT syndrome,
and catecholaminergic polymorphic VT.
MIRACLE (11), COMPANION (12), and MADIT-
CRT (13) established the base for CRT. The COMPA-
NION study enrolled patients with low LVEFs, QRS
duration  120 ms, and NYHA Class III or IV (the only
study to evaluate ICDs in NYHA Class IV), and showed
that CRT improved LVEF, heart failure symptoms, and
reduced the mortality rate in patients with NYHA Class
IIIIV heart failure and wide QRS interval regardless of
ischemic or non-ischemic etiology. MADIT-CRT showed
ICDs decrease non-fatal heart failure events in mild
CHF (NYHA Classes I and II), LVEF B30%, and QRS
duration  130 ms. It further proved that patients with a
QRS duration  150 ms benefit from CRT the most.
Methods
Translating the results of these emerging studies became
critical to our clinical practice for patient care at a
community-based hospital. We established ICD/CRT
inclusion/exclusion criteria in our hospital by integrating
the results of these major trials.
Over 450 patients who were admitted to our hospital
during the past year for either ICD implantation or for
ICD-related events were extensively reviewed; among
these, 13 cases were selected to represent major indica-
tions and contraindications of ICDs in our practice.
These cases presented here cover ICD indications for the
secondary prevention of SCD, primary prevention of
SCD in patients with CHF that resulted from either CAD
or non-ischemic cardiomyopathy, and indications for
infiltrative cardiomyopathy and inherited conditions.
A greater than 1 year of life expectancy with reasonable
functionality is a prerequisite to qualify for a device.
We also discussed the potential benefits of ICDs with
and without CRT in certain populations of patients that
have not been adequately evaluated by currently available
RCTs, including alcoholic, elderly, female, or end-stage
renal disease (ESRD)/hemodialysis (HD) patients. Finally,
we addressed the risks, complications, and contraindica-
tions of ICDs, as well as the application of an external
wearable defibrillator, which has comparable survival
benefit with ICDs (14), in AMI or status post (s/p)-
CABG during the mandatory waiting period for an ICD.
Results
Table 1 shows the inclusion/exclusion criteria of ICD/
CRTs in our hospital. These criteria are based on updated
CRT results and recommendations. Execution of these
criteria improves the adherence and compliance of ICD
guidelines for daily patient care in our hospital.
In Table 2, we list 13 cases representing the most
common clinical situations encountered in our clinical
practice during last year. For each case, a brief clinical
history, the electrophysiology study results leading to
a guideline-supported device indication (as referenced
in Table 1), and the final treatment delivered are out-
lined. A 12-lead EKG for each case is also shown follow-
ing the table. Major categories of patients include: 1)
patients who meet primary or secondary ICD criteria;
2) patients who meet exclusion criteria; 3) patients who
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criteria for CRT.
Special considerations
The potential benefits of ICDs with/without CRT in
certain patient populations have not been adequately
evaluated by currently available RCTs.
Alcoholic cardiomyopathy and ICD
The ICD is indicated for cardiac arrhythmia and/or
CHF associated with alcoholic cardiomyopathy. Alcohol
can trigger atrial fibrillation, which can make an ICD
fire inappropriately. Although new versions of ICD can
distinguish atrial fibrillation from other lethal arrhyth-
mias and therefore have less inappropriate firings, ab-
staining from alcohol is a must for patients with alcoholic
cardiomyopathy.
Age, gender, and ICDs
Both the elderly ( 80 years old) and female patients
are underrepresented in current ICD trials, even though
about 20% of ICDs are implanted in these two patient
populations. Meta-analysis data from available trials
suggest that ICDs do not reduce overall mortality in
the elderly, which is likely due to a higher incidence of
non-arrhythmic death as compared with younger patients
(15). However, due to small population sizes in these
studies as well as wide confidence intervals (95% CI,
0.291.08), we do not consider age to be exclusion
criterion in our practice. Similarly, meta-analysis data
also found that ICDs do not confer significant overall
mortality benefit in women (16). This is believed to be
because SCD has a weaker impact on total mortality
in women than in men  hence, the higher ICD benefit
in men. Further larger-scale studies focusing on these
patient populations are warranted, and careful risk
stratification in clinical practice is important to avoid
overgeneralization of current ICD recommendations.
ESRD and ICD
While up to 10% of ESRD patients have an ICD
implanted, the survival benefit in this population is
unclear (17), most likely due to the presence of multiple
severe comorbidities. Transvenous ICD leads are asso-
ciated with central vein stenosis resulting in significant
adverse consequences for arteriovenous access (in up
to 20% of ESRD patients). Infections associated with
ICD leads are more frequent and associated with worse
outcomes in ESRD patients (18). An external wearable
defibrillator is an alternative for ESRD patients who do
not yet meet criteria for permanent ICD therapy or are
experiencing serious side effects.
Complications
Other than venous stenosis and systemic or local infec-
tions, patients can experience discomfort associated with
Table 1. Easton Hospital ICD criteria
Secondary prevention
1. Documented episodes of cardiac arrest due to VT/VF,
not due to a transient or reversible cause
2. Documented sustained VT, either spontaneous or induced
by EP, not associated with AMI and not due to a transient or
reversible cause.
Primary prevention
1. Documented familiar or inherited conditions with high risk of
life-threatening VT, such as long QTsyndrome, hypertrophic
obstructive cardiomyopathy, etc.
2. CAD with all of the following:
Prior MI  40 days (MADIT I & MUSTT)
LVEF B35%
VT/VF inducible and sustained at EP study
EP study greater than 4 weeks post-qualifying MI
3. Prior MI with all of the following (MADIT II):
LVEF B30%
NYHA Class II or III
No cardiogenic shock or hypertension in stable rhythm
4. Ischemic dilated cardiomyopathy with both of the following
(SCD-HeFT):
NYHA Class II or III
LVEF B35%
5. Non-ischemic dilated cardiomyopathy with all of the
following (SCD-HeFT):
Documented duration  3 months
NYHA Class II or III
LVEF B35%
6. Severe CHF with all of the following:
Meets coverage requirements for CRT
NYHA Class IV
QRS  120 ms
Exclusion criteria
1. MI B40 days
2. CABG or PCI B90 days
3. NYHA Class IV who do not meet requirements for CRT Rx
4. Candidate for coronary revascularization
5. VT/VF or CHF due to reversible cause
6. No reasonable expectation of survival with a good functional
status for more than 1 year.
Class I recommendation for CRT
LVEF B30%
Dilated LV cavity with severe systolic dysfunction
Recurrent CHF (NYHA Class III or ambulatory Class IV) despite
optimal medical therapy,  39 months in duration
QRS duration  120 ms (best responders: LBBB and QRS-d
 150 ms)
Ventricular tachyarrhythmia (VT/VF)
Sinus rhythm best response (AV synchrony and VV synchrony)
CHF, congestive heart failure; CRT, cardiac resynchronization
therapy; ICD, implan cardioverter defibrillator; LVEF, left ventricular
ejection fraction; NYHA, New York Heart Association; Rx, treatment;
VF, ventricular fibrillation; VT, ventricular tachycardia.
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to anxiety as well as panic disorders and even agorapho-
bia. One of our recent studies showed that underlying
malignancy is also a significant risk factor for ICD
pocket infection (19).
Conclusions
The ICD has a wide spectrum of clinical applications.
A thorough understanding of its indications is critically
important in daily practice. At our hospital, ICD inclu-
sion and exclusion criteria have been established based
Table 2. Cases discussion of the criteria described in Table 1
# Clinical vignette EPS etc Indication Rx
1 
74 yo M, w/ remote MI; recurrent CHF despite max med Rx, 
NYHA class III, LVEF <20% 
HV: 74msec, inducible
sustained VT, Abnl SA node
fxn. QRSd: 128mSec 
SP-2, 
PP-2,3,4; CRT 
BiV-DDDR/
ICD 
2  52 yo M w/ h/o heavy alcohol abuse p/w recurrent CHF, NYHA 
II-III, cardiac cath negative for CAD, LVEF 10–15% 
Inducible sustained VT
deteriorating to VF, abnl SA
node fxn 
SP-2, 
PP-5 
DDDR/ICD  
3 
35 yo W developed recurrent CHF post-partum despite max 
medical therapy, non-compliant w/ med, NYHA class worsens 
from II to III, LVEF deteriorate from 40% to 20%  
Inducible sustained PMVT,
abnl SA node fxn.
QRSd: 138 mSec 
SP-2, PP-5; 
CRT 
BiV-DDDR/
ICD 
4 
74 yo M, h/o severe ischemic cardiomyopathy, recurrent CHF,
p/w elevated troponin. On optimal med. LVEF <25%. Cardiac 
cath: severe 3 vessel disease not amendable to revascularization. 
SA & AV node dysfunction
Sustained PMVT.
QRSd: 127 mSec 
EC-1 SP-2, 
PP-2,3 
Life-Vest for 
40days BiV-
DDDR/ICD
5 
37 yo M p/w recurrent near syncope. Documented sustained 
monomorphic VT. Cardiac cath and echo nl. He’s diagnosed with
right ventricular dystrophy. Had recurrent VT despite VT  
ablation for scar modification.  
Heart MRI: pachy fibrofatty
replacement of the RV
myocardium 
SP-2 
VT ablation 
DDDR/ICD 
6 
27 yo W w/ h/o TOF, s/p definitive repair and PV replacement,
p/w recurrent near syncope. No CAD on cardiac cath and LV fxn nl 
Sustained macro-renetrant
monomorphic VT 
SP-2 DDDR/ICD 
7 
86 yo W p/w dizziness and hypotension with monomorphic VT 
that required immediate cardiovertion. Cardio cath showed 80% 
RCA stenosis, for which she got 3 BMS. LVEF: 30%. QT 
interval: 450 mSec 
LV  
aneurysm 
EC-2 
SP-1,2 
Life-Vest for 
90days BiV-
DDDR/ICD
8 
47 yo  W developed acute CHF (NYHA III) after URI. Echo: LV
dilation, LVEF< 10%. No CAD on cardiac cath. Responded to
med & LVEF back to 55%. LVEF dropped to <15% after 1 year
off meds, but back to >45% 4 months after meds are resumed.  
Normal EPS study  EC-5 
Life-Vest for 4 
months 
No ICD 
indicated 
9 
29 yo AAM p/w SOB, palpitation. Non-sustained WCT on EKG.
Sarcoidosis suggested by chest CT and confirmed by bronchial 
Bx 
Cardiac MRI: delayed
gadolinium enhancement in
myocardium. 
EPS: Sustained PMVT. 
SP-2 DDDR/ICD 
10 
35 yo W p/w recurrent near syncope. h/o type 1 myotonic 
dystrophy.  
HV: 101 msec. Sustained 
monomorphic VT.  
SP-2 DDDR/ICD 
11 41 yoM p/w palpitations and near-syncope, h/o severe HOCM
evidenced by TTE. LVEF 50-55%. Family history positive for 
HOCM. He developed recurrent A-fib. 
Abnl SA node fxn. 
Sustained monomorphic 
v-tach.
SP-2, PP-1 DDDR/ICD
12 59 yoM w/ h/o osteosarcoma on chronic methadone, admitted
for “flu” symptoms, transient confusion and unresponsive-
ness. Developed two episodes of sustained PMVT requiring
immediate cardioversion while in house. Cardio cath: no 
significant CAD, LVEF 50-55%.
temporary pacemaker to 
prevent bradycardia-
induced symptomatic 
polymorphic v-tach. 
EC - 5 life-vest, 
tapering 
methadone
13 34 yoM w/ h/o recurrent syncope p/w cardia arrest due to
v-fib. Successful ACLS.  EKG: Brugada, type 1.
inconclusive SP-1,  PP-1 DDDR/ICD
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practical and up to date. They help to standardize patient
care in terms of ICD/CRT implantation. It is evident
from our cases that we stress on contraindications,
mandatory waiting periods and maximal/optimal medical
therapy prior to device implantation. Case 8 and 12, in
particular, highlight reversible causes of VT/VF as exclu-
sion criteria. We believe this represents a practical
translation of emerging CRTs that results in better patient
care in our practice at a community-based hospital.
Further study is certainly necessary to assess the impact
of the ICD Criteria in our institution by comparing
implant appropriateness both before and after the institu-
tion of the criteria with significant randomized samples
sizes.
ICDs are indeed beneficial in selected patients. Mor-
tality benefits have not been proven in female patients,
the elderly, ESRD, and non-ischemic cardiomyopathy
patients. In addition, ICD shocks can be painful, reduce
quality of life, and increase anxiety in patients. Patients
should be well informed of all benefits and risks of the
ICD before implantation.
Table 2. (Continued)
Case 10 
Case 2 
12 lead EKG of Table 2
Case 3 
Case 6  Case 5 
Case 8  Case 9 
Case 11 
Case 13 
Case 1 
Case 4 
Case 7 
Case 12 
EKG interpretations: 
Case 1: SR, IVCD w/ QRSd of 128 
msec.  
Case 2: SR, narrow QRS.  
Case 3: SR, 1° AVB, LBBB, QRSd of 
138 msec  
Case 4: SR, LBBB, QRSd: 127 msec 
Case 5: SR, RBBB 
Case 6: SR, RBBB-like +LAFB 
morphology 
Case 7: Ventricular tachycardia  
Case 8: Poor R progression 
Case 9: PVC w/ R-on-T, 4-beats VT. 
Case 10: SR, 1° AVB, non-specific 
IVCD with 105 msec. 
Case 11: Prominent voltage with 
repolarization changes consistent w/ 
HOCM. 
Case 12: SR, QT interval: 592 mSec 
Case 13: Brugada, type 1 
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